{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T21:10:20Z","timestamp":1774818620681,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["physicamedica.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physica Medica"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ejmp.2018.12.036","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T23:11:08Z","timestamp":1546557068000},"page":"100-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin\u2019s disease"],"prefix":"10.1016","volume":"57","author":[{"given":"Kalliopi M.","family":"Kourinou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michalis","family":"Mazonakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efrosini","family":"Lyraraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen \u0391.","family":"Papadaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Damilakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmp.2018.12.036_b0005","series-title":"Perez & Brady\u2019s principles and practice of radiation oncology","author":"Halperin","year":"2013"},{"key":"10.1016\/j.ejmp.2018.12.036_b0010","series-title":"Statistics Review, 1975\u20132015","author":"Noone","year":"2018"},{"issue":"3","key":"10.1016\/j.ejmp.2018.12.036_b0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11899-017-0385-y","article-title":"Role of radiation therapy in the treatment of Hodgkin Lymphoma","volume":"12","author":"Gonzalez","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ejmp.2018.12.036_b0020","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/258797","article-title":"Role of radiotherapy in modern treatment of Hodgkin\u2019s Lymphoma","volume":"2011","author":"Yeoh","year":"2011","journal-title":"Adv Hematol"},{"issue":"8","key":"10.1016\/j.ejmp.2018.12.036_b0025","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.ejmp.2018.12.036_b0030","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s Lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejmp.2018.12.036_b0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","article-title":"Hodgkin lymphoma: late effects of treatment and guidelines for surveillance","volume":"53","author":"Ng","year":"2016","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.ejmp.2018.12.036_b0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","article-title":"Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment","volume":"2016","author":"Van Leeuwen","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.ejmp.2018.12.036_b0045","first-page":"4045","article-title":"Intermediate stage Hodgkin\u2019s disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy","volume":"24","author":"Anselmo","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejmp.2018.12.036_b0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1748-717X-2-13","article-title":"A comparison of mantle versus involved-field radiotherapy for Hodgkin\u2019s lymphoma: reduction in normal tissue dose and second cancer risk","volume":"2","author":"Koh","year":"2007","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.ejmp.2018.12.036_b0055","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/485071","article-title":"The role of radiotherapy in Hodgkin\u2019s lymphoma: what has been achieved during the last 50 years?","volume":"2015","author":"Witkowska","year":"2015","journal-title":"BioMed Res Int"},{"issue":"19","key":"10.1016\/j.ejmp.2018.12.036_b0060","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejmp.2018.12.036_b0065","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ijrobp.2009.05.012","article-title":"Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study","volume":"75","author":"Weber","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ejmp.2018.12.036_b0070","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/annonc\/mdr439","article-title":"Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy","volume":"23","author":"Campbell","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejmp.2018.12.036_b0075","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"4","key":"10.1016\/j.ejmp.2018.12.036_b0080","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl. 1","key":"10.1016\/j.ejmp.2018.12.036_b0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: issues in delineating the radiation field in Hodgkin\u2019s disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejmp.2018.12.036_b0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4682-8-27","article-title":"Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy","volume":"8","author":"Schneider","year":"2011","journal-title":"Theor Biol Med Model"},{"issue":"5","key":"10.1016\/j.ejmp.2018.12.036_b0095","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ijrobp.2004.12.040","article-title":"Estimation of radiation-induced cancer from three-dimensional dose distributions: concept of organ equivalent dose","volume":"61","author":"Schneider","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejmp.2018.12.036_b0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-8-22","article-title":"Hodgkin\u2019s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms","volume":"8","author":"Cella","year":"2013","journal-title":"Radiat Oncol Lond Engl"},{"issue":"7","key":"10.1016\/j.ejmp.2018.12.036_b0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2015.03.005","article-title":"Involved node, site, field and residual volume radiotherapy for lymphoma: a comparison of organ at risk dosimetry and second malignancy risks","volume":"27","author":"Murray","year":"2015","journal-title":"Clin Oncol J"},{"issue":"2","key":"10.1016\/j.ejmp.2018.12.036_b0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/rpd\/ncy050","article-title":"Second cancer risk from radiation therapy for common solid tumors diagnosed in reproductive-aged females","volume":"182","author":"Mazonakis","year":"2018","journal-title":"Radiat Prot Dosimetry"},{"issue":"11","key":"10.1016\/j.ejmp.2018.12.036_b0115","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1118\/1.4932394","article-title":"Radiotherapy for stage I seminoma of the testis: organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model","volume":"42","author":"Mazonakis","year":"2015","journal-title":"Med Phys"},{"issue":"4","key":"10.1016\/j.ejmp.2018.12.036_b0120","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1118\/1.4944422","article-title":"Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas","volume":"43","author":"Mazonakis","year":"2016","journal-title":"Med Phys"},{"issue":"7","key":"10.1016\/j.ejmp.2018.12.036_b0125","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1002\/mp.12327","article-title":"Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma","volume":"44","author":"Mazonakis","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.ejmp.2018.12.036_b0130","series-title":"Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2","author":"Council","year":"2006"},{"issue":"4","key":"10.1016\/j.ejmp.2018.12.036_b0135","first-page":"1","article-title":"United states life tables, 2014","volume":"66","author":"Arias","year":"2017","journal-title":"Natl Vital Stat Rep"},{"issue":"3","key":"10.1016\/j.ejmp.2018.12.036_b0140","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/bjc.2017.177","article-title":"Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors","volume":"117","author":"Van Eggermond","year":"2017","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejmp.2018.12.036_b0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.radonc.2014.06.018","article-title":"Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy","volume":"112","author":"Mulvihill","year":"2014","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ejmp.2018.12.036_b0150","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ijrobp.2010.05.035","article-title":"Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients","volume":"81","author":"Weber","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ejmp.2018.12.036_b0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/02841860510029833","article-title":"The use of risk estimation models for the induction of secondary cancers following radiotherapy","volume":"44","author":"Da\u015fu","year":"2005","journal-title":"Acta Oncol Stockholm Sweden"},{"issue":"3","key":"10.1016\/j.ejmp.2018.12.036_b0160","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1088\/0031-9155\/60\/3\/1237","article-title":"Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy","volume":"60","author":"Murray","year":"2015","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ejmp.2018.12.036_b0165","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmp.2017.02.015","article-title":"Models for the risk of secondary cancers from radiation therapy","volume":"4","author":"Dasu","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.ejmp.2018.12.036_b0170","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejmp.2017.03.011","article-title":"Risk of secondary cancers: bridging epidimiology and modeling","volume":"42","author":"Schneider","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.ejmp.2018.12.036_b0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejmp.2017.02.013","article-title":"Photons-radiobiological issues related to the risk of second malignancies","volume":"42","author":"Marcu","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.ejmp.2018.12.036_b0180","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejmp.2017.02.001","article-title":"Out-of-field doses in radiotherapy: input to epidimiological studies and dose \u2013 risk models","volume":"42","author":"Harrison","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.ejmp.2018.12.036_b0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmp.2017.10.004","article-title":"Risk of second cancer following radiotherapy","volume":"42","author":"Toma-Dasu","year":"2017","journal-title":"Phys Med"},{"issue":"1","key":"10.1016\/j.ejmp.2018.12.036_b0190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Physica Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1120179718313760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1120179718313760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T16:57:32Z","timestamp":1549817852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1120179718313760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":38,"alternative-id":["S1120179718313760"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmp.2018.12.036","relation":{},"ISSN":["1120-1797"],"issn-type":[{"value":"1120-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Physica Medica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmp.2018.12.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}